TABLE 1.
General and clinical features of the study population
| Parameter | Value | CI |
|---|---|---|
| Gender, n (%) | ||
| Male | 27 (58.7) | 95% CI, 43.2–73 |
| Female | 19 (41.3) | 95% CI, 27–56.8 |
| Age (years), mean ± SD | 64.5 ± 12 | 95% CI, 61–68 |
| Days from COVID‐19 symptoms onset, mean ± SD | 6.9 ± 2.2 | 95% CI, 6.3–7.5 |
| CT‐SS, mean ± SD | 15.2 ± 10.7 | 95% CI, 12.1–18.3 |
| Clinical findings, n (%) | ||
| Fever | 38 (82.6) | 95% CI, 68.5–92.2 |
| Asthenia | 41 (89.1) | 95% CI, 76.4–96.4 |
| Cough | 28 (60.9) | 95% CI, 45.3–74.9 |
| Chest pain | 3 (6.5) | 95% CI, 1.4–17.9 |
| Appetite loss | 39 (84.8) | 95% CI, 71.1–93.7 |
| Joint pain | 41 (89.1) | 95% CI, 76.4–96.4 |
| Muscle pain | 40 (87) | 95% CI, 73.7–95.1 |
| Headache | 35 (76.1) | 95% CI, 61.2–87.4 |
| Diarrhoea | 6 (13) | 95% CI, 4.9–26.3 |
| Abdominal pain | 8 (17.4) | 95% CI, 7.8–31.4 |
| Nausea | 8 (17.4) | 95% CI, 7.8–31.4 |
| Conjunctivitis | 1 (2.2) | 95% CI, 0.05–11.5 |
| Urticaria | 0 (0 ) | 97.5% CI, 0–7.7 |
| Sticky throat mucus | 16 (35 ) | 95% CI, 21.3–50.2 |
| Nasal obstruction | 19 (41.3 ) | 95% CI, 27–56.8 |
| Rhinorrhoea | 21 (45.6 ) | 95% CI, 30.9–61 |
| Nasal burning | 17 (37 ) | 95% CI, 23–51 |
| Throat pain | 12 (26.1 ) | 95% CI, 13.4–38.9 |
| Ear pain | 3 (6.5) | 95% CI, 1.4–17.9 |
| Face pain | 1 (2.2) | 95% CI, 0.05–11.5 |
| Swallowing difficulties | 17 (37 ) | 95% CI, 23–51 |
| Voice issues | 3 (6.5) | 95% CI, 1.4–17.9 |
| Mouth burning | 3 (6.5) | 95% CI, 1.4–17.9 |
| Taste loss | 31 (67.4) | 95% CI, 52–80.5 |
| Baseline psychophysical olfactory function assessment, n (%) | ||
| Normal | 11 (23.9) | 95% CI, 12.6–38.8 |
| Mild hyposmia | 0 (0) | 97.5% CI, 0–0.8 |
| Moderate hyposmia | 13 (28.3) | 95% CI, 16–43.5 |
| Severe hyposmia | 10 (21.7) | 95% CI, 10.9–36.4 |
| Anosmia | 12 (26.1) | 95% CI, 14.3–41.1 |
| Baseline self‐reported olfactory function assessment, n (%) | ||
| Normal | 15 (32.6) | 95% CI, 19.5–48 |
| Partial loss | 18 (39.1) | 95% CI, 25.1–54.6 |
| Total loss | 13 (28.3) | 95% CI, 16–43.5 |
| 60‐Day psychophysical olfactory function assessment (n = 42), n (%) | ||
| Normal | 20 (47.6) | 95% CI, 32–63.6 |
| Mild hyposmia | 11 (26.2) | 95% CI, 13.9–42 |
| Moderate hyposmia | 5 (11.9) | 95% CI, 4–25.6 |
| Severe hyposmia | 3 (7.1) | 95% CI, 1.5–19.5 |
| Anosmia | 3 (7.1) | 95% CI, 1.5–19.5 |
| 60‐Day self‐reported olfactory function assessment, n (%) | ||
| Normal | 32 (76.2) | 95% CI, 60.6–87.9 |
| Partial loss | 8 (19) | 95% CI, 8.6–34.1 |
| Total loss | 2 (4.8) | 95% CI, 0.6–16.2 |
Abbreviations: CI, confidence interval; COVID‐19, coronavirus disease 2019; CT‐SS, computed tomography severity score; SD, standard deviation.